PROMETHEUS BIOSCIENCES INC (RXDX)       108.68  +0.25 (+0.23%)

108.68  +0.25 (+0.23%)

US74349U1088 - Common Stock - After market: 108.68 0 (0%)

News Image
a month ago - Prometheus Biosciences

Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...

News Image
2 months ago - The Motley Fool

Is Prometheus Biosciences a Good Stock to Buy Right Now?

This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.

News Image
2 months ago - Prometheus Biosciences

Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...

News Image
2 months ago - The Motley Fool

Why Shares of Prometheus Biosciences Are Soaring This Week

The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.

News Image
2 months ago - FinancialNewsMedia

Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END

News Image
2 months ago - FinancialNewsMedia.com

Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which...

News Image
2 months ago - Seeking Alpha

Hot Stocks: CVNA crashes more than 40%; ASO jumps on earnings; SWBI drops; RXDX skyrockets

CVNA plunges more than 40%. ASO climbs on earnings news. SWBI declines on quarterly results. RXDX skyrockets on clinical data.

News Image
2 months ago - Prometheus Biosciences

Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...

News Image
2 months ago - InvestorPlace

PINS Stock Alert: What to Know as Pinterest and Elliott Strike a Deal

Pinterest (PINS) stock is on the move Wednesday as investors react to an agreement with Elliott Investment Management L.P.

News Image
2 months ago - InvestorPlace

Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today?

Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials.

News Image
2 months ago - Investor's Business Daily

Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease

Prometheus Biosciences made waves Wednesday in irritable bowel disease.

News Image
2 months ago - The Motley Fool

These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday

Even as broader markets fell, these companies announced great news.

News Image
2 months ago - Seeking Alpha

Prometheus stock surges 190% as inflammatory bowel disease drug shows efficacy in trials

Prometheus Biosciences (RXDX) said its medicine PRA023 showed strong efficacy and favorable safety in two mid stage trials in patients with ulcerative colitis ((UC)) and Crohn’s...